A user's six month progress with Pyrilutamide, a hair loss treatment; they experienced positive results such as stopped itching and shedding, as well as regrowth, without any side effects.
The user is treating hair loss with dermarolling, a laser helmet, scalp massages, and Nizoral. They stopped using minoxidil and finasteride and are considering pumpkin seed oil and sulforaphane.
Discussing and researching different treatments for hair loss, including RU58841, Dutasteride, Spironolactone, Retin-A, Stemoxydine (Neogenic), Copper peptides, Superoxide Dismutase, NANO, and Eucapil.
The user mixes their own RU58841 solution and found that increasing the ethanol content improved absorption and reduced scalp itching. A study on minoxidil showed that penetration increased with higher ethanol concentrations, reaching maximum penetration at 90% ethanol.
A user shared an extensive hair loss treatment regimen including dutasteride, minoxidil, tadalafil, RU58841, microneedling, and various topical and oral supplements. Responses varied, with some suggesting the regimen is excessive and others offering additional advice or expressing skepticism about its practicality and effectiveness.
Magnesium L-Threonate may help treat balding by reducing DKK-1 expression without affecting DHT. Users discuss its potential effectiveness and application methods, with some considering trying it topically.
OP is using 5% minoxidil and a needler to regrow hair after chemotherapy-induced hair loss. Another user mentions using finasteride and topical minoxidil, noting some improvement in hair density.
Hair loss treatments include finasteride, minoxidil, microneedling, dutasteride, CB-03-01, RU-58841, and experimental options like KY-19382 and stem cell therapy. Some treatments are considered ineffective or risky, such as ketoconazole, PRP, and low-level laser therapy.
The user experienced noticeable hair regrowth using topical minoxidil and a dermaroller within a month. They are advised to consider DHT inhibition for lasting results.
PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.
The conversation discusses affordable low-level light therapy (LLLT) products for hair loss, with users debating the effectiveness of red LEDs versus lasers. The original poster is already using finasteride, minoxidil, ketoconazole, and microneedling, and is seeking budget-friendly LLLT options to add to their regimen.
The conversation is about hair regrowth using micro-needling, RU58841, oral and topical minoxidil, ketoconazole shampoo, and dutasteride. Users suggest that noticeable results take longer than two weeks, though one user mentions seeing baby hairs.
Aminexil/Kopexil may help reduce hair loss by addressing perifollicular fibrosis in androgenetic alopecia, but it lacks the extensive clinical backing of finasteride and minoxidil. Some users find it effective, but availability and cost are issues, especially in the US where it's not FDA-approved.
Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.
A user who has been using the "Big 3" hair loss treatments (ketoconazole, minoxidil and finasteride) for 2-3 months and is hoping to see positive results. The other user commented that they look like a hyper responder and asked if they were using oral or topical fin/min.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references upcoming trial data from Shiseido in Japan.
The conversation is about a user's two-year hair loss treatment progress using 1mg oral finasteride daily, Kirkland minoxidil twice a day, and Nizoral 1% shampoo three times a week. The user reports no side effects and attributes most progress to finasteride and minoxidil.
The conversation discusses using minoxidil and Koshine for hair loss. It suggests applying them separately with a 5-minute gap and using Koshine on dry hair.
The conversation is about skepticism towards the hair loss treatments RU58841 and Pyrilutamide, with users discussing the lack of human testing for RU58841 and the ongoing trials for Pyrilutamide. Some users believe RU58841 has more anecdotal success, while others highlight Pyrilutamide's current research progress.
GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
Hair loss treatment progress with Dut, Min, Keto, needling, and RU/Min/Fin/Dut topical. User noticed improvement, believes RU and needling most effective.
The conversation is about a 25-year-old male's one-year hair loss treatment progress using 0.25mg finasteride daily and 2% ketoconazole shampoo. The user shared progress pictures trying to maintain consistent lighting for comparison.
RepliCel has purchased Trichoscience, and they have a video about hair multiplication. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.
The post discusses a user's 2-month progress in treating hair loss using topical Du once a week, microneedling, and red light therapy. The user notes that red light therapy is primarily for face and body inflammation but also applies it to the scalp.
The conversation is about using Xeljanz for hair regrowth in individuals with LPP. The user is seeking experiences and expectations from others who have tried this treatment.
The conversation discusses potential hair loss treatments, including methylating estrogen, losing body fat, and supplementing with vitamins A, K2, and D. It also mentions reducing exposure to environmental estrogenics, with skepticism about genetic factors being the primary cause of baldness.